|Fei Jiean： Risk Stratification of Lung Nodule||Target User||Sensitivity & Specificity||Detecting Application Process||Contact Us|
Fei Jiean is ANN (Artificial Neural Networks) what is a machine learning algorithm to use in conjunction with blood tests for aid to stratify the malignant probablity of lung nodule.
Fei Jiean is developed by 20/20 GeneSystems Inc., and marketed in China by My-Biomed Biotechnology Co., Ltd (MBM)
Fei Jiean Detection Report contains of malignant probability of lung nodules (risk score), 95% CI, and stratification of malignancy risk of lung nodules (high risk, middle risk,low risk)
Fei Jiean characteristics of target user: age ≥ 50 year old, and ≥ 20 pack-year history of smoking, and smoking cessation < 15years, following a CT scan lung nodule size ≥10mm, at least one of biomarker-tumor (CEA/NSE/CYFRA21-1) is shown positive.
Fei Jiean is a tool of risk stratification of lung nodules following a CT scan, combined with biomarker-tumor blood test and clinical factors.
Fei Jiean is an algorithm which is built and valildated with data from over 1,000 patients tested at Thoracic Dept in one of top China Oncology Hospitals, 502 lung cancer cases vs 501 benign lung nodules controls.
Result for malignancy probability assessment: AUC=0.894, Specificity 90%, Sensitivity 70.9%.
Fei Jiean has aligned malignancy probability assessment with varied lung nodule size.
Fei Jiean has aligned malignancy probability assessment for varied types of lung cancer.
Fei Jiean Wechat Platform
Mail box: email@example.com
Official website: www.my-biomed.com